Clinical Policy 1A-41: Office-Based Opioid Treatment

Tuesday, March 30, 2021

Based on the American Society of Addiction Medicine (ASAM) practice guidelines for treatment of opioid use disorder and March 2020 FDA guidance, Clinical Coverage Policy 1A-41, Office-Based Opioid Treatment is being updated to add buprenorphine for the treatment of patients aged 16 years and older.

There is no longer a recommendation for failed withdrawal attempts for patients 16 through 17 years of age seeking medication assisted treatment, so this requirement will be removed effective May 1, 2021.


NCTracks Call Center: 800-688-6696